Retatrutide Research

Retatrutide CAS Number and Chemical Identity

Reviewed by our laboratory team · Last updated 2026-07-03

Retatrutide's CAS Registry Number is 2381089-83-2. It is also indexed on PubChem and referenced as LY3437943 in Eli Lilly filings. Its molecular formula reflects a 39-residue peptide with C20 diacid fatty-acid conjugation and approximate molecular weight of 4,731 Da.

Key facts

CAS Number
2381089-83-2
Internal code
LY3437943
Molecular weight
~4,731 Da
Class
Synthetic peptide

How to verify chemical identity

Research-grade retatrutide should ship with a Certificate of Analysis showing HPLC purity and mass-spectrometry confirmation of the expected mass (~4,731 Da). CAS number matching is a first-pass identity check only.

Extended research context

The Retatrutide Research deep dive

Deep dive: how the triple-agonist scaffold was engineered

Retatrutide's 39-residue backbone was designed by Eli Lilly's peptide chemistry team to preserve the pharmacophores of three glucagon-family receptors on a single chain. The N-terminal domain retains GIP-receptor contacts, mid-chain substitutions restore GLP-1-receptor affinity lost in native GIP, and additional residue swaps confer glucagon-receptor engagement. A γGlu-2xOEG linker anchors a C20 fatty diacid at Lys17, which reversibly binds serum albumin and slows renal clearance — the same albumin-tethering strategy Novo Nordisk pioneered with semaglutide and Lilly refined further in tirzepatide.

The TRIUMPH Phase 3 programme in context

TRIUMPH is Lilly's global Phase 3 development umbrella for retatrutide, spanning obesity (TRIUMPH-1 through TRIUMPH-4), type 2 diabetes, MASH (metabolic dysfunction-associated steatohepatitis), and knee osteoarthritis linked to obesity. Readouts began in 2025 and continue through 2026. Because the compound is investigational, no regulator — FDA, EMA, or MHRA — has issued marketing authorisation, and legitimate supply exists only for laboratory reference and research contexts, never for human administration.

How retatrutide differs from tirzepatide and semaglutide at the mechanism level

Semaglutide is a mono-agonist (GLP-1 only). Tirzepatide is a dual agonist (GIP + GLP-1). Retatrutide adds glucagon-receptor activity, which pre-clinical and Phase 2 data suggest contributes to energy expenditure in addition to appetite regulation and glucose-dependent insulin release. This three-receptor combination is why retatrutide is sometimes called a 'metabolic multi-tool' peptide in the trade press — but the pharmacology is more nuanced than the label implies.

Research applications

  • In vitro receptor-binding assays across GIP-R, GLP-1R and GCGR panels
  • Comparator studies alongside semaglutide, tirzepatide and liraglutide reference standards
  • Analytical-method development: HPLC retention profiling and LC-MS confirmation
  • Stability testing of lipidated 39-residue peptides in aqueous and lyophilised forms
  • Reference material for teaching incretin pharmacology in university-level courses

Handling checklist

  • Store lyophilised vials at −20 °C; protect from light and humidity
  • Reconstitute with bacteriostatic water; avoid vortexing (foams the peptide)
  • Once reconstituted, store at 2–8 °C and use within 28 days
  • Verify batch CoA — HPLC ≥98%, mass matches ~4,731 Da, endotoxin low
  • Do not administer to humans or animals — research use only

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

Confusing retatrutide with tirzepatide in supplier catalogues

Fix: Cross-check the LY code (LY3437943 = retatrutide; LY3298176 = tirzepatide) and the receptor profile on the CoA.

Using tap or filtered water for reconstitution

Fix: Only use bacteriostatic water for injection (0.9% benzyl alcohol) or sterile water — never lab DI water.

Storing reconstituted solution at room temperature

Fix: Refrigerate at 2–8 °C immediately after reconstitution; discard after 28 days.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Related questions researchers ask

  • Is retatrutide the same molecule as LY3437943?
  • What is the correct spelling: retatrutide or retatrutid?
  • Is retatrutide a GLP-1 drug?
  • Which company makes retatrutide?
  • When will retatrutide be FDA approved?
  • Is retatrutide legal in the UK?

Frequently asked questions

Does the CAS number confirm purity?
No — CAS confirms identity of the compound, not purity of a batch. HPLC and MS data on the CoA confirm batch quality.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab (external, rel="nofollow").

More Retatrutide Research articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.